These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer.
    Author: Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH.
    Journal: Anticancer Res; 2007; 27(1B):641-5. PubMed ID: 17348454.
    Abstract:
    BACKGROUND: Weekly paclitaxel and infusional high-dose 5-fluorouracil/leucovorin (HDFL) are both effective regimens for metastatic breast cancer (MBC) patients. PATIENTS AND METHODS: A study was designed using weekly paclitaxel 90 mg/m(2) 1-hour infusion followed by 2,000 mg/m(2) 5-fluorouracil plus 300 mg/m(2) leucovorin 24-hour infusion on days 1, 8 and 15, repeated every 28 days, in patients who had previously received a > or =1 regimen for MBC. The dose of paclitaxel was adjusted in each cycle according to toxicity. RESULTS: A total of 182 cycles were given to 28 patients. The doses of paclitaxel needed to be reduced only in 22 (12%) cycles. Forty-five cycles were skipped or delayed more than 7 days, mostly due to neutropenia, infection, or neurotoxicity. Twenty-five patients were evaluable for response. Four had complete response, 13 partial response, seven stable disease, and two progressive disease. The response rate was 60.7% (95% CI: 42.6-78.8). Median survival was 18.1 months (95% CI: 11.4-24.9), and progression-free survival seven months. CONCLUSION: Weekly paclitaxel plus infusional HDFL is an active and well tolerated regimen for pretreated MBC patients.
    [Abstract] [Full Text] [Related] [New Search]